Lycopene (Herb/Suppl)

Brand and Other Names:all-trans lycopene, psi-carotene, more...psi-psi-carotene, solanrubin
  • Print

Suggested Dosing

General Dosing Guidelines

Pure comopound: 13-75 mg/day PO

Capsule: 10-30 mg BID PO

Prostate Cancer

15 mg BID PO

Oral Leukoplakia

4-8 mg/day PO

Specific lycopene supplement (LycoRed)

Preventing Exercise-induced Asthma

30 mg/day PO

Next:

Suggested Uses

Cancer, preventing atherosclerosis, cardiovascular disease, prostate cancer, HPV infection, cataracts, asthma, antioxidant, & anti-inflammatory

Efficacy

Bladder & colon cancer: There is no association between lycopene and the risk of cancer

Cardiovascular disease: Conflicting studies; more studies are needed to determine effectiveness

Atherosclerosis: Insufficient information

Oral leukoplakia: Preliminary evidence suggests significant clinical response

Ovarian, pancreatic prostate, & lung cancer: Evidence suggests it may reduce risk

HPV: Research suggests that women with higher levels of lycopene cleared oncogenic HPV in an average of 8.5 months compared to 11-12 months in women with lower levels

Previous
Next:

Adverse Effects

None reported

Previous
Next:

Warnings

Contraindications

None reported

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: avoid use

Lactation: avoid use

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Metabolism: N/A

Excretion: N/A

Mechanism of Action

Antioxidant with particular affinity for prostate

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.